Biosimilarity : (Record no. 71109)

000 -LEADER
fixed length control field 02513nam a2200517Ii 4500
001 - CONTROL NUMBER
control field 9781315368344
005 - DATE AND TIME OF LATEST TRANSACTION
control field 20220531132340.0
006 - FIXED-LENGTH DATA ELEMENTS--ADDITIONAL MATERIAL CHARACTERISTICS
fixed length control field m o d
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 181112t20182017fluab ob 001 0 eng d
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
International Standard Book Number 9781315368344
-- (e-book : PDF)
035 ## - SYSTEM CONTROL NUMBER
System control number (OCoLC)1057341765
040 ## - Cataloging Source
-- FlBoTFG
-- FlBoTFG
-- rda
041 1# -
-- eng
050 #4 - LIBRARY OF CONGRESS CALL NUMBER
Classification number RS67.U6
Item number N539 2018
072 #7 -
-- MED
-- 009000
-- bisacsh
072 #7 -
-- MED
-- 071000
-- bisacsh
072 #7 -
-- TDCW
-- bicscc
082 04 -
-- 615.10973
100 1# - MAIN ENTRY--PERSONAL NAME
Personal name Niazi, Sarfaraz K.,
Relator term author.
245 10 - TITLE STATEMENT
Title Biosimilarity :
Remainder of title The FDA Perspective /
Statement of responsibility, etc. by Sarfaraz K. Niazi.
250 ## - EDITION STATEMENT
Edition statement First edition.
264 #1 -
-- Boca Raton, FL :
-- CRC Press,
-- [2018].
264 #4 -
-- ©2017.
300 ## - PHYSICAL DESCRIPTION
Extent 1 online resource (436 pages) :
Other physical details 79 illustrations, text file, PDF
336 ## -
-- text
-- rdacontent
337 ## -
-- computer
-- rdamedia
338 ## -
-- online resource
-- rdacarrier
504 ## - BIBLIOGRAPHY, ETC. NOTE
Bibliography, etc Includes bibliographical references and index.
505 00 -
-- Current Status of Biosimilar Biological Products. The FDA Position. Biosimilarity Tetrahedron. Analytical and Functionality Similarity. Non-clinical Assessment. Clinical Pharmacology Assessment. Clinical Studies. Interchangeability Status. Comprehensive Presentation
520 3# -
-- The focus of this book is on how the US FDA will approve biosimilar drugs. The European scene is well developed with specific guidelines that are already in place. However, these guidelines do not apply to the thinking of the FDA in approving these products. The FDA is quite different from other regulatory agencies. With the US providing more than 50% of the worldwide market for these products, every serious manufacturer of biosimilar biological drugs should be targeting US approval of their products. Thus, this book is strictly on FDA approval strategy.
530 ## -
-- Also available in print format.
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Drugs
General subdivision Generic substitution.
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Pharmaceutical biotechnology
Geographic subdivision United States.
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Pharmaceutical biotechnology.
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Biosimilar Pharmaceuticals.
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Drug Approval.
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Government Regulation.
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element United States Government Agencies.
650 #7 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element MEDICAL / Pharmacology.
Source of heading or term bisacsh
655 #0 -
-- Electronic books.
710 2# - ADDED ENTRY--CORPORATE NAME
Corporate name or jurisdiction name as entry element Taylor and Francis.
776 08 -
-- Print version:
-- 9781498750394
856 40 -
-- https://www.taylorfrancis.com/books/9781315368344
-- Click here to view.

No items available.

Technical University of Mombasa
Tom Mboya Street, Tudor 90420-80100 , Mombasa Kenya
Tel: (254)41-2492222/3 Fax: 2490571